Targeting CD166 lung cancer stem cells: Molecular study using murine dendritic cell vaccine
/in Dendritic Cells, International Publications, NSCLC, SCLC /von 2021-08-23 / Toxicol Appl Pharmacol 2021 Oct;429:115699Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-08-20 / Front Immunol 2021;12:669965Curcumin as an Adjuvant to Cancer Immunotherapy
/in Curcuma, International Publications /von 2021-08-16 / Front Oncol 2021;11:675923Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 2618)Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma.
/in Dendritic Cells, International Publications, Soft Tissue Sarcoma /von 2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 11542)Dendritic Cells Pulsed with Cytokine-Adjuvanted Tumor Membrane Vesicles Inhibit Tumor Growth in HER2-Positive and Triple Negative Breast Cancer Models
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-08-04 / Int J Mol Sci 2021 Aug;22(16)Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-08-01 / Anticancer Res 2021 Aug;41(8):4133-4141Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-08-01 / Melanoma Res 2021 Aug;31(4):378-388
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution